Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

This House of Representative Just Sold Up To $250K In Bristol-Myers Squibb Stock

Published 27/12/2022, 15:05
Updated 27/12/2022, 16:11
© Reuters.  This House of Representative Just Sold Up To $250K In Bristol-Myers Squibb Stock

Benzinga - The Office of Texas Representative Nicholas V. Taylor has reported a sale of Bristol-Myers Squibb (NYSE:BMY) stock on December 26, 2022. According to the Periodic Transaction Report the transaction was placed on December 26, 2022.

What Happened: A recent report from the House of Representatives Clerk's Office on December 26, 2022 reveals that Taylor made a sale of Bristol-Myers Squibb stock valued between $100,001 - $250,000.

Bristol-Myers Squibb shares are trading down 0.44% at $72.57 at the time of writing.

Why Congressional Transactions Matter Congressional transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.

A Congressional transaction is when any Representative or Senator either buys or sells an individual stock. Anyone working in Congress must file a Periodic Transaction Report to inform the public of their recent transaction within 30 days of being notified of the transaction and within 45 days of the transaction date.

When a Senator or Representative makes a new purchase, that could be an indication that they expect the stock to rise.

A sale, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down.

In April 2012, Former President Barack Obama signed the STOCK Act into law. The act prohibits members of Congress from using private information given to them by their position for personal gain such as buying or selling a stock. The act also expanded disclosure requirements for members of Congress by requiring them to file a monthly disclosure.

Trade Recap A December filing states that Texas Representative Nicholas V. Taylor sold shares of Bristol-Myers Squibb. The exact amount of the transaction remained unknown but the filing states a range of $100,001 - $250,000.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.